List view / Grid view
12 April 2018 | By Dr Zara Kassam (Drug Target Review)
Technique measuring the cccDNA marker may allow earlier detection of hepatocellular carcinoma in patients...
26 March 2021 | By Victoria Rees (Drug Target Review)
Researchers have created an immune assay that can profile host immune responses to infection and is faster than current methods.
13 September 2019 | By NanoTemper Technologies
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
11 December 2018 | By Matthias Nees and Malin Åkerfelt (University of Turku - Finland)
Drug discovery is still hampered by the routine use of cell-based models that often fail to recapitulate the truly relevant biological complexity of the corresponding disease. Just moving from two- (2D) towards three-dimensional (3D) cell culture model systems like spheroids and organoids is not enough to generate truly representative and…
16 July 2018 | By Catherine Lautenschlager (PerkinElmer), Hong Cao (PerkinElmer)
AlphaLISA® provides a robust assay that facilitates the design and development of antibody therapeutics.
12 September 2017 | By Daniel Cardillo, Jeanine Hinterneder, Matthew Marunde, Vincent Dupriez
In this application note, PerkinElmer discuss how their ValiScreen CXCR2 GPCR cell line (#ES-145-C) was utilised to examine the downstream effects of chemokine receptor modulation using multiple blocking antibodies and a small molecule...
20 September 2016 | By Christophe Thierry (Galapagos NV), Jan Van der Schueren (Galapagos NV), Jans Mia (Galapagos NV), Nicolas Houvenaghel (Galapagos NV)
In vitro high-throughput cellular target-based assays are commonly used for hit identification targeting G-protein coupled receptors (GPCR). Agonist and antagonist identification of GPCRs often relies on the screening of large collections of chemicals using miniaturised in vitro cell-based functional assays. In the panel of assays, calcium mobilisation measured by aequorin…
12 September 2016 | By Cisbio Bioassays
This technical note gives you critical insights into on how to run, optimise and validate this ERK assay on your own cellular materials...
16 June 2016 | By Drug Target Review
Drug Target Review talks to Joseph Jammal, Chief Operating Officer of Cisbio Bioassays, to find out more about assay developments and future innovations in this area of drug discovery...
21 September 2015 | By SomaLogic
The SOMAscan™ assay is a highly multiplexed, sensitive, quantitative and reproducible proteomic tool for discovering biomarkers for drug discovery...
5 July 2021 | By Dr Robert Hewitt (Biosample Hub)
Dr Robert Hewitt explains why the need of biospecimen brokers to protect their commercially-sensitive information can result in significant issues for industry end-users and the results of their research.
22 June 2021 | By Robert Skolik (University of Louisville)
A major limitation in drug development is the occurrence of drug-candidate toxicity during clinical research. This may occur because tumour-derived cell lines are limited as a pre-clinical model – in part because of an altered metabolic poise. A recent study has revealed a profound plasticity in gene expression and metabolic poise that can…
22 June 2021 | By Dr Thomas Schubert (2bind)
Optimisation of a hit towards a lead happens in a variety of ways, as a lead needs to meet various criteria such as activity, affinity to the target, selectivity, solubility, permeability or metabolic stability to become a promising candidate. A balance between in vitro profiles and pharmacokinetic attributes has to…
10 June 2021 | By Dr Jo Brewer (Adaptimmune)
Dr Jo Brewer outlines research into allogeneic products by gene editing stem cells, which has the potential to build a broad family of multiple immune cell types, including T-cell therapies.
17 May 2021 | By Victoria Rees (Drug Target Review)
Microfluidic screening technologies have been used to discover a promising antibody candidate against SARS-CoV-2 and the South African variant.
